BioLineRx Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLRX research report →
Price Chart
About the company
BioLineRx Ltd. , an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
- CEO
- Philip A. Serlin
- IPO
- 2011
- Employees
- 22
- HQ
- Hevel Modi'in, HM, IL
Get TickerSpark's AI analysis on BLRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.80M
- P/E
- -0.99
- PEG
- 0.00
- P/S
- 6.57
- P/B
- 0.60
- EV/EBITDA
- -1.11
- Div Yield
- 0.00%
- Gross Margin
- 69.79%
- Op Margin
- -874.34%
- Net Margin
- -574.17%
- ROE
- -47.22%
- ROIC
- -50.11%
Latest fiscal year · YoY change
- Revenue
- $1.19M-95.9%
- Gross Profit
- $430.39K-97.8%
- Op Income
- $-10,368,606
- Net Income
- $-1,184,321+87.2%
- EPS
- $-0.29+93.7%
- OCF Growth
- +81.5%
- FCF Growth
- +81.4%
- 52W High
- $3.95
- 52W Low
- $0.78
- 50D MA
- $2.05
- 200D MA
- $2.63
- Beta
- 0.70
- RSI (14)
- 11
- Avg Volume
- 22.86K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioLineRx highlighted encouraging early GLIX1 clinical progress and new preclinical combination data, while APHEXDA royalties and cash runway support operations into the first half of 2027.· August 31, 2026
- GLIX1 Phase I/IIa in glioblastoma and other high-grade gliomas is progressing on plan, with dosing now in the second of 5 planned Phase I cohorts and Phase I data still expected in the first half of 2027.
- Management said GLIX1 has shown favorable safety and tolerability to date, plus strong preclinical activity in GBM models and synergy with the PARP inhibitor olaparib in HR-proficient ovarian cancer.
- APHEXDA generated $1.6 million in second-quarter sales for Ayrmid, translating into $0.3 million of royalty revenue to BioLineRx.
- Quarterly revenue was $0.3 million, net loss was $4.3 million, and cash, cash equivalents and short-term bank deposits were $13.1 million at quarter-end.
- The company also completed a $3.75 million registered direct offering after quarter-end and said it remains funded into the first half of 2027.
Revenue for the quarter ended June 30, 2026 was $0.3 million, flat versus the prior-year quarter. R&D expenses were $2.9 million, up from $2.3 million a year ago, while G&A expense was $0.9 million versus $0.2 million, with the prior-year period benefiting from a reversal of a $0.8 million doubtful-account provision. Nonoperating expenses were $0.7 million versus $1.9 million, and net loss was $4.3 million compared with $3.9 million in the 2025 quarter. On the operating side, APHEXDA sales were $1.6 million in Q2 2026, producing $0.3 million of royalty revenue. The company ended the quarter with $13.1 million of cash, cash equivalents and short-term bank deposits and said that, together with the post-quarter $3.75 million offering, it is funded into the first half of 2027.
Phil Serlin framed the quarter around GLIX1, calling it a first-in-class oral small molecule with a novel mechanism and emphasizing its brain penetration, safety profile, and potential across multiple cancers. He stressed that recruitment in the glioblastoma study is going extremely well, that the trial remains on schedule, and that the ovarian cancer synergy data open the door to additional development options and potential PARP inhibitor partnerships. His tone was upbeat but measured, repeatedly noting that the program is still early.
Mali Zeevi focused on the quarter’s core financials: $0.3 million of revenue, $2.9 million of R&D, $0.9 million of G&A, $0.7 million of nonoperating expenses, and a $4.3 million net loss. She explained that R&D increased mainly due to the new GLIX1 project, while G&A was distorted by a prior-year reversal of a $0.8 million doubtful-account provision tied to a Gloria milestone payment. She also confirmed quarter-end liquidity of $13.1 million, plus the $3.75 million post-quarter financing, supporting the stated runway into the first half of 2027.
Analysts focused on three issues: where GLIX1 plus PARP inhibition could fit in ovarian cancer, whether the Revolution daraxonrasib approval changes the PDAC strategy, and how APHEXDA is progressing in transplant centers amid generic competition. Management said the ovarian program is still too early for a firm line-of-therapy decision, but the data support multiple development options and ongoing discussions with key opinion leaders. For PDAC, management acknowledged the treatment landscape may change but said there is still room for motixafortide/CXCR4 inhibition and they are waiting for the interim/futility analysis before deciding next steps. On APHEXDA, Serlin said the transplant market takes time to change standard operating procedures, noted generics were already present at launch, and said Ayrmid is putting in the effort to drive adoption.
The bullish case is that GLIX1 is moving ahead on schedule with early human dosing, encouraging safety/tolerability, and a growing preclinical package that includes GBM efficacy and ovarian combination synergy. Management also pointed to ongoing APHEXDA royalties and a cash runway into the first half of 2027, reducing near-term financing pressure.
The main risks are that GLIX1 is still very early, with Phase I data not expected until the first half of 2027, so most of the value proposition remains unproven. APHEXDA sales are still modest, pancreatic-cancer strategy may need reassessment after competing advances, and management did not commit to a clear ovarian-cancer path yet because the data are early and discussions are ongoing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.1%
- Shares Outstanding
- 4.98M
- Float Shares
- 4.14M
of shares held by institutions
16 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 473.00K | ▲ 473.00K |
| Citadel Advisors LLC | 30.09K | ▲ 15.29K |
| Susquehanna International Group, Llp | 20.55K | ▼ 10.36K |
| Stifel Financial Corp | 20.04K | ▲ 20.04K |
| Renaissance Technologies LLC | 18.90K | ▲ 3.49K |
| Rhumbline Advisers | 2.48K | 0 |
| Wells Fargo & Company/Mn | 1.75K | ▼ 250 |
| Nemes Rush Group LLC | 250 | 0 |
| Tower Research Capital LLC (Trc) | 181 | ▲ 181 |
| Ubs Group AG | 157 | ▲ 56 |
| Newedge Advisors, LLC | 82 | 0 |
| Osaic Holdings, Inc. | 51 | ▲ 25 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Yan Shaoyu | other | 0 |
| Jan 1, 25 | PANEM SANDRA | other | 0 |
| Oct 3, 22 | PANEM SANDRA | other | 0 |
| Oct 3, 24 | PANEM SANDRA | other | 0 |
| Oct 3, 23 | PANEM SANDRA | other | 0 |
| Oct 2, 19 | PANEM SANDRA | other | 0 |
| Oct 2, 21 | PANEM SANDRA | other | 0 |
| Oct 2, 20 | PANEM SANDRA | other | 0 |
| Oct 5, 16 | PANEM SANDRA | other | 0 |
| Oct 5, 18 | PANEM SANDRA | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLRX coverage
Recent articles, reports, and earnings notes.
No research on BLRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLRX report →BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
prnewswire.com · Nov 18
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
prnewswire.com · Nov 18
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
gurufocus.com · Nov 16
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
prnewswire.com · Nov 16
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
prnewswire.com · Oct 23
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
prnewswire.com · Oct 8
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
prnewswire.com · Sep 10
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.